Cargando…

Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.

During a population-based screening project for breast cancer, almost 15,000 women aged 50 years and over have provided a 12 h (overnight) sample of urine for research purposes. In 3,789 women the excretion of 11-desoxy-17-oxosteroids (DOOS) and creatinine was measured. Results were analysed in term...

Descripción completa

Detalles Bibliográficos
Autores principales: Poortman, J., van der Smissen, J., Collette, H. J., de Waard, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1979
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009999/
https://www.ncbi.nlm.nih.gov/pubmed/444408
_version_ 1782136229249155072
author Poortman, J.
van der Smissen, J.
Collette, H. J.
de Waard, F.
author_facet Poortman, J.
van der Smissen, J.
Collette, H. J.
de Waard, F.
author_sort Poortman, J.
collection PubMed
description During a population-based screening project for breast cancer, almost 15,000 women aged 50 years and over have provided a 12 h (overnight) sample of urine for research purposes. In 3,789 women the excretion of 11-desoxy-17-oxosteroids (DOOS) and creatinine was measured. Results were analysed in terms of urinary concentrations and of a ratio between DOOS and creatinine. Age had an effect on DOOS, creatinine and their ratio. Body weight and body surface area had an effect on creatinine excretion and therefore on the ratio. The following variables did not have an appreciable effect on the above-mentioned ratio: a family history of breast cancer, parity and age at first pregnancy, menopause and oestrogenic drugs, and parenchymal pattern of the breast as observed on the xeromammogram. Breast cancer was found at first screening in 106 out of 14,697 women. In 100 of these cases DOOS and creatinine were measured. Excretion values expressed as the ratio between the two, allowing for body surface area, did not differ materially from those of 100 age-matched controls. These results lead the authors to the conclusion that the determination of androgen metabolite excretion in women over 50 years of age is of no help in selecting a group at high risk of breast cancer.
format Text
id pubmed-2009999
institution National Center for Biotechnology Information
language English
publishDate 1979
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20099992009-09-10 Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer. Poortman, J. van der Smissen, J. Collette, H. J. de Waard, F. Br J Cancer Research Article During a population-based screening project for breast cancer, almost 15,000 women aged 50 years and over have provided a 12 h (overnight) sample of urine for research purposes. In 3,789 women the excretion of 11-desoxy-17-oxosteroids (DOOS) and creatinine was measured. Results were analysed in terms of urinary concentrations and of a ratio between DOOS and creatinine. Age had an effect on DOOS, creatinine and their ratio. Body weight and body surface area had an effect on creatinine excretion and therefore on the ratio. The following variables did not have an appreciable effect on the above-mentioned ratio: a family history of breast cancer, parity and age at first pregnancy, menopause and oestrogenic drugs, and parenchymal pattern of the breast as observed on the xeromammogram. Breast cancer was found at first screening in 106 out of 14,697 women. In 100 of these cases DOOS and creatinine were measured. Excretion values expressed as the ratio between the two, allowing for body surface area, did not differ materially from those of 100 age-matched controls. These results lead the authors to the conclusion that the determination of androgen metabolite excretion in women over 50 years of age is of no help in selecting a group at high risk of breast cancer. Nature Publishing Group 1979-06 /pmc/articles/PMC2009999/ /pubmed/444408 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Poortman, J.
van der Smissen, J.
Collette, H. J.
de Waard, F.
Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
title Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
title_full Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
title_fullStr Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
title_full_unstemmed Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
title_short Ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
title_sort ratio of 11-desoxy 17-oxosteroids to creatinine in a population screened for breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009999/
https://www.ncbi.nlm.nih.gov/pubmed/444408
work_keys_str_mv AT poortmanj ratioof11desoxy17oxosteroidstocreatinineinapopulationscreenedforbreastcancer
AT vandersmissenj ratioof11desoxy17oxosteroidstocreatinineinapopulationscreenedforbreastcancer
AT collettehj ratioof11desoxy17oxosteroidstocreatinineinapopulationscreenedforbreastcancer
AT dewaardf ratioof11desoxy17oxosteroidstocreatinineinapopulationscreenedforbreastcancer